CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leading player in the field of conditionally activated, localized biologics, has announced the appointment of Yu-Waye (Wayne) Chu, M.D. as its Chief Medical Officer (CMO). With his extensive experience in the clinical development of Probody® therapeutic candidates, Dr. Chu is set to oversee the Company’s diversified portfolio and take it to the next level.
Wayne brings an impressive background to CytomX with his extensive experience in oncology drug development strategy that has been used in approvals of various therapeutic modalities, such as antibody drug conjugates, checkpoint inhibitors, and bispecific immunotherapies.
He comes to CytomX during an exciting time, as multiple clinical trials are set to take place for CX-904, the new INDs CX-2051 and CX-801, and the effort to target CD71. With Wayne now at the helm, CytomX is primed to make significant progress in its innovative and differentiated pipeline.
Dr. Chu is delighted and proud to be part of CytomX at a time when its pipeline is on track to make immense clinical impact with its Probody® Platform. With a suite of drug candidates born from localized biologics and the potential to generate considerable near- and long-term value for those struggling with cancer, Dr. Chu is excited to join the team with the shared goal of delivering novel and enhanced treatments.
Dr. Wayne Chu has joined CytomX with an impressive career spanning two decades in the field of oncology. Most recently, he served as Chief Medical Officer of Fate Therapeutics, where he crafted the development of novel immune cell therapies to combat both hematologic and solid tumor malignancies.
Before Fate, Dr. Chu spent ten years at Genentech, expanding his roles and responsibilities in Product Development Oncology, including leading the clinical development of molecules such as polatuzumab vedotin, tiragolumab, and mosunetuzumab. His early career was rooted in clinical training at Johns Hopkins School of Medicine and the National Cancer Institute, following his undergraduate degree in Molecular Biology from Princeton University and M.D. obtaining honours in research from the University of Rochester School of Medicine and Dentistry.
About CytomX Therapeutics
At CytomX, we are revolutionizing the field of oncology by pushing the boundaries of current treatments. Our Probody® technology platform enables us to create highly effective therapies such as localized, conditionally activated biologics; antibody-drug conjugates (ADCs); T-cell engaging bispecific antibodies (TCBs); and immune modulators.
We have a clinically advanced potential treatment for CD71, CX-2029, and a CTLA-4-targeting Probody therapeutic, BMS-986288, in collaboration with Bristol Myers Squibb. Additionally, we are developing CX-904 in partnership with Amgen, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) and CD3 receptor on tumor cells.
Our preclinical pipeline is also impressive, offering CX-801, an interferon alpha-2b Probody cytokine, and CX-2051, a conditionally activated ADC directed toward EpCAM. We are proud to partner with some of the leading names in oncology, such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. As we continue to